Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (113)

« Back to Publications

Review of the British Thoracic Society Winter Meeting 26–29 November 2025

Flynn CA. et al, (2026), Thorax

Real-World Effectiveness and Safety of Single Inhaler Triple Therapy with Beclometasone/ Formoterol/ Glycopyrronium in Moderate to Severe Asthma: TriMaximize Study

Gessner C. et al, (2026), Journal of Asthma and Allergy, Volume 19, 1 - 21

Commentary on the 2024 British Thoracic Society Specialty Trainee Survey report

Russell REK., (2025), Thorax

The Risk–Benefit Balance of Oral Corticosteroid Treatment for Asthma Attacks: A Discrete Choice Experiment of Patients and Healthcare Professionals in the UK and New Zealand

Howell I. et al, (2025), Respirology, 30, 1035 - 1045

Response: To the Comment on AI-Assisted Spirometry Interpretation in Primary Care: A Randomized Controlled Trial

Doe G. et al, (2025), NEJM AI, 2

Identification and management of cardiopulmonary risk in patients with chronic obstructive pulmonary disease: a multidisciplinary consensus and modified Delphi study.

Gale CP. et al, (2025), European journal of preventive cardiology, 32, 1445 - 1460

Validation of artificial intelligence spirometry diagnostic support software in primary care: a blinded diagnostic accuracy study

Sunjaya A. et al, (2025), Erj Open Research, 11

Chronotherapy in asthma: BD or not BD? That is the question

Smallcombe N. and Russell RE., (2025), Thorax, 80, 487 - 488

AI-Assisted Spirometry Interpretation in Primary Care: A Randomized Controlled Trial

Doe G. et al, (2025), NEJM AI, 2

Exploring patients’ and carers’ experiences, understandings and expectations of COPD exacerbations:an interview study

Hutchinson A. et al, (2025), BJGP Open, 9, BJGPO.2024.0026 - BJGPO.2024.0026

Management and mechanisms of eosinophil action in asthma: mind the gap?

Russell REK., (2025), The Lancet Respiratory Medicine, 13, 190 - 191

Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial

Ramakrishnan S. et al, (2025), The Lancet Respiratory Medicine, 13, 59 - 68

Blood Eosinophil Counts in Healthy Volunteers and in Patients with Asthma and COPD in India: A Multi-Centre Cross-Sectional Report.

Dhar R. et al, (2025), International journal of chronic obstructive pulmonary disease, 20, 3867 - 3875

Phase 2a, Randomized Trial of Mitiperstat Versus Placebo in Patients with COPD at High Risk of Exacerbation (CRESCENDO).

Hughes R. et al, (2025), International journal of chronic obstructive pulmonary disease, 20, 3305 - 3315

COPD as a comorbidity of asthma

Cass S. and Russell REK., (2025), Ers Monograph, 2025, 342 - 351

Load More

1
2
3
4
5
6
7
...
»